Multiple bullish factors boost pharmaceutical Hong Kong stocks. Institutions say they still face this risk in the short term.

①What are the policy measures to support the field of innovative drugs? ②What unfavorable effects on domestic pharmaceutical stocks might Trump's election bring about?

cls.cn21:59 ET

*Special Treat Jingfeng (000908.SZ): The holding subsidiary is planning to authorize and act as an agent for pharmaceutical products with related parties.

gelonhui on November 11th: *ST Jingfeng (000908.SZ) announced that its holding subsidiary Shanghai Jingfeng Pharmaceutical Co., Ltd. is planning to engage in daily related party transactions of authorized agent pharmaceutical products with its affiliate Hebei Zhongcheng Pharmaceutical Co., Ltd. (referred to as "Zhongcheng Pharmaceutical") for development needs. The amount of the related party transaction is expected to be no more than 30 million RMB, and the above limit is valid for one year from the date of approval by the shareholders' meeting. The main content of this daily related party transaction is for Shanghai Jingfeng to sell sodium glycoxylate injection to Zhongcheng Pharmaceutical and authorize Zhongcheng Pharmaceutical for exclusive sales promotion and distribution nationwide.

Gelonghui FinanceNov 11 06:28 ET

An Intrinsic Calculation For CSPC Pharmaceutical Group Limited (HKG:1093) Suggests It's 47% Undervalued

Simply Wall StNov 5 23:42 ET

CSPC Pharma (01093.HK) will hold a board of directors meeting on November 15 to approve the performance for the first three quarters.

Granting Investment Network November 5th cspc pharma (01093.HK) announced that the board of directors meeting of the company will be held on November 15, 2024, to approve the unaudited consolidated performance announcement of the company and its subsidiaries for the nine months ended September 30, 2024.

Gelonghui FinanceNov 5 05:04 ET

CSPC PHARMA: DATE OF BOARD MEETING

HKEXNov 5 05:02 ET · Announcements

[Brokerage Focus] Zhongtai International cuts CSPC Pharma (01093) target price by 15%, indicating that its performance in the first three quarters will be lower than market expectations.

Jingu financial news | CICC International issues research reports, stating that CSPC Pharma (01093) has issued a profit warning. Due to the significant decrease in the main business revenue of the pharmaceutical business in the third quarter compared to the second quarter, the net income of shareholders in the first three quarters of the company will decrease by 16% year-on-year to approximately 0.38 billion yuan. The main reasons for the decline in pharmaceutical business revenue are: 1) a widening decline in oncology business revenue in the third quarter; 2) poor performance of core products in the central nervous system and cardiovascular fields. The company's performance in the first three quarters will be below market expectations. The report points out that in the short term, oncology drugs still face challenges, and sales of core products in the central nervous system and cardiovascular fields are difficult to recover quickly. FY24-26E oncology

Jinwu Financial NewsNov 3 21:15 ET